Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery
NCT ID: NCT04812951
Last Updated: 2023-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
101 participants
INTERVENTIONAL
2021-02-17
2022-02-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intraocular Steroid After Cataract Surgery Study
NCT00478764
Ocular Penetration of Topical Tacrolimus Eye Drops
NCT02794610
Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
NCT01367249
Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery
NCT04542759
Optimal Method for Mydriasis in Cataract Surgery
NCT02909140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
young control
25 patients \< 65 years old without any prophylactic anti-inflammatory preoperative treatment
No interventions assigned to this group
control
25 patients \> 75 years old without any prophylactic anti-inflammatory preoperative treatment
No interventions assigned to this group
Study group
25 patients \> 75 years old with prophylactic anti-inflammatory preoperative treatment
CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion
one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
Vehicle group
25 patients \> 75 years old with vehicle preoperative treatment
cationorm eye drops
one cationorm eye drop twice a day for 30 preoperative days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CycloSPORINE Ophthalmic 0.1% Ophthalmic Emulsion
one cyclosporine 0.1% eye drop twice a day for 30 preoperative days
cationorm eye drops
one cationorm eye drop twice a day for 30 preoperative days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Postmenopausal women for whom cataract surgery has been scheduled
* Stage N2-3; C1-2 according (Lens Opacities classification System) LOCS
* Willing to sign informed consent and fully participate to all length of the study
* Patients without any previous medical history of ocular and/or systemic inflammatory, autoimmune or auto inflammatory disease
* Patient with no history of ocular surgery
* Patients without any previous or concomitant ocular diseases
Exclusion Criteria
* Patients on systemic or local therapy with drugs that alter the secretion of the tear film (beta blockers, antidepressants and psychotropics)
* Patients with a history of allergic, congenital, autoimmune systemic diseases
* Patients who have undergone previous eye surgery
* Ocular or peri-ocular malignancies or premalignant conditions
* Active or suspected ocular or peri-ocular infection.
* Complicated Cataract Surgery
* Patients with a positive pregnancy testAllergy or reaction history to study drug
* Patients who participated in a clinical trial in which an investigational drug was administered within 30 days or 5 half-lives of the study drug
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Campus Bio-Medico University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonio Di Zazzo
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Campus Bio Medico
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gupta PK, Drinkwater OJ, VanDusen KW, Brissette AR, Starr CE. Prevalence of ocular surface dysfunction in patients presenting for cataract surgery evaluation. J Cataract Refract Surg. 2018 Sep;44(9):1090-1096. doi: 10.1016/j.jcrs.2018.06.026. Epub 2018 Aug 2.
Kim JS, Lee H, Choi S, Kim EK, Seo KY, Kim TI. Assessment of the Tear Film Lipid Layer Thickness after Cataract Surgery. Semin Ophthalmol. 2018;33(2):231-236. doi: 10.1080/08820538.2016.1208764. Epub 2016 Sep 14.
Trattler WB, Majmudar PA, Donnenfeld ED, McDonald MB, Stonecipher KG, Goldberg DF. The Prospective Health Assessment of Cataract Patients' Ocular Surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017 Aug 7;11:1423-1430. doi: 10.2147/OPTH.S120159. eCollection 2017.
Iglesias E, Sajnani R, Levitt RC, Sarantopoulos CD, Galor A. Epidemiology of Persistent Dry Eye-Like Symptoms After Cataract Surgery. Cornea. 2018 Jul;37(7):893-898. doi: 10.1097/ICO.0000000000001491.
Kohli P, Arya SK, Raj A, Handa U. Changes in ocular surface status after phacoemulsification in patients with senile cataract. Int Ophthalmol. 2019 Jun;39(6):1345-1353. doi: 10.1007/s10792-018-0953-8. Epub 2018 Jun 20.
Kasetsuwan N, Satitpitakul V, Changul T, Jariyakosol S. Incidence and pattern of dry eye after cataract surgery. PLoS One. 2013 Nov 12;8(11):e78657. doi: 10.1371/journal.pone.0078657. eCollection 2013.
Micera A, Di Zazzo A, Esposito G, Longo R, Foulsham W, Sacco R, Sgrulletta R, Bonini S. Age-Related Changes to Human Tear Composition. Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):2024-2031. doi: 10.1167/iovs.17-23358.
Di Zazzo A, Micera A, De Piano M, Cortes M, Bonini S. Tears and ocular surface disorders: Usefulness of biomarkers. J Cell Physiol. 2019 Jul;234(7):9982-9993. doi: 10.1002/jcp.27895. Epub 2018 Dec 4.
Olivieri F, Prattichizzo F, Grillari J, Balistreri CR. Cellular Senescence and Inflammaging in Age-Related Diseases. Mediators Inflamm. 2018 Apr 17;2018:9076485. doi: 10.1155/2018/9076485. eCollection 2018. No abstract available.
Baker JR, Vuppusetty C, Colley T, Hassibi S, Fenwick PS, Donnelly LE, Ito K, Barnes PJ. MicroRNA-570 is a novel regulator of cellular senescence and inflammaging. FASEB J. 2019 Feb;33(2):1605-1616. doi: 10.1096/fj.201800965R. Epub 2018 Aug 29.
Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. Clin Mol Allergy. 2017 Dec 14;15:21. doi: 10.1186/s12948-017-0077-0. eCollection 2017.
Torricelli AA, Santhiago MR, Wilson SE. Topical cyclosporine a treatment in corneal refractive surgery and patients with dry eye. J Refract Surg. 2014 Aug;30(8):558-64. doi: 10.3928/1081597X-20140711-09.
Di Zazzo A, Micera A, Coassin M, Varacalli G, Foulsham W, De Piano M, Bonini S. InflammAging at Ocular Surface: Clinical and Biomolecular Analyses in Healthy Volunteers. Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1769-1775. doi: 10.1167/iovs.18-25822.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSA2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.